72.11.Z - Research and experimental development on biotechnology
21.20.Z - Manufacture of medicines and other pharmaceutical products
47.29.Z - Other retail sale of food in specialised stores
47.73.Z - Dispensing chemist in specialised stores
47.91.Z - Retail sale via mail order houses or via Internet
62.01.Z - Computer programming activities
72.19.Z - Other research and experimental development on natural sciences and engineering
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
86.22.Z - Specialist medical practice activities
86.90.E - Other human health activities notelsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -0,1 | 0,1 | -1,9 | -2793,9 |
EBITDA | 0,4 | 0,7 | -1,1 | -267,1 |
Short time liabilities | 0,6 | 0,3 | 0,5 | 56,1 |
Equity capital | 4,2 | 4,3 | 2,8 | -36,7 |
Operating profit (EBIT) | -0,1 | 0,3 | -1,5 | -621,4 |
Assets | 13,9 | 14 | 13 | -7,5 |
Net profit (loss) | -0,1 | 0,2 | -1,6 | -815,5 |
Cash | 6,3 | 6,4 | 0,9 | -86,7 |
Net income from sale | 4 | 4,3 | 4,3 | 0,1 |
Liabilities and provisions for liabilities | 9,7 | 9,7 | 10,2 | 5,6 |
Working assets | 7,5 | 7,8 | 6,7 | -14 |
Depreciation | 0,5 | 0,4 | 0,4 | 11,5 |
% | % | % | p.p. | |
Profitability of capital | -3,2 | 5,1 | -57,9 | -63 |
Equity capital to total assets | 30,5 | 31 | 21,2 | -9,8 |
Gross profit margin | -3,4 | 1,6 | -44,3 | -45,9 |
EBITDA Margin | 9,9 | 15,7 | -26,2 | -41,9 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 51 | 28 | 44 | 16 |
Current financial liquidity indicator | 2.566049814224243 | 2.97489857673645 | 2.4829609394073486 | -0,5 |
Net dept to EBITDA | 1.1838116645812988 | 0.978323221206665 | -5.934833526611328 | -6,9 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane